pharmaceutical-technology.com
88%
541
Reimbursement of telemedicine services could continue even after the abatement of COVID-19 pandemic: Poll
The analysis is based on 368 responses received from the readers of Verdict’s Pharmaceutical Technology site between 18 June and 20 July.Consumers of telemedicine services in the US increased to 46% compared to 11% before the COVID-19 pandemic, according to a report from McKinsey and Company, which notes that approximately $250bn in US healthcare spending is expected to shift towards telemedicine after the pandemic ends. Effectiveness compared to in-person visits, security, and reimbursement continues to remain crucial in the future success of telemedicine services.